ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag tuberculosis biotech fda cancer

2022 Top 10 Innovations 
2022 Top 10 Innovations
The Scientist | Dec 12, 2022 | 10+ min read
This year’s crop of winning products features many with a clinical focus and others that represent significant advances in sequencing, single-cell analysis, and more.
Take Two of These
Bob Grant | Jun 22, 2011 | 6 min read
Drugmakers are teaming up to test the disease-fighting power of combination therapies earlier in the development cycle than ever before.
Top 10 Innovations 2021
2021 Top 10 Innovations
The Scientist | Dec 1, 2021 | 10+ min read
The COVID-19 pandemic is still with us. Biomedical innovation has rallied to address that pressing concern while continuing to tackle broader research challenges.
High-Priced Biotech Drugs: Are They Worth It?
Susan Warner(swarner@the-scientist.com) | Dec 5, 2004 | 6 min read
4,000 for a course of treatment.
Pharmaceutical And Biotech Firms Taking On Drug-Resistant Microbes
Kathryn Brown | Jun 9, 1996 | 9 min read
Drug-Resistant Microbes As pesky pathogens continue to evolve, new technologies to combat them are emerging, spelling job opportunities for molecular biologists and chemists. OBSTINATE MICROBES: Margaret Rennels cites strains of pneumococcus resistence to two major drugs. At drug and biotech companies across the United States, scientists have set their sights on a most elusive target: drug-resistant microbes. Working in pharmaceutical- biotechnology partnerships, researchers are trying every
Venture Capital, with a Twist
Ted Agres(tagres@the-scientist.com) | Jul 17, 2005 | 5 min read
Jamie Heywood, chief executive of the Amyotrophic Lateral Sclerosis Therapy Development Foundation (ALSTDF), founded the nonprofit biotech company in 1999 after his brother was diagnosed with ALS.
Therapeutic MAbs: Saving Lives and Making Billions
Kelli Miller Stacy(kstacy@the-scientist.com) | Feb 13, 2005 | 8 min read
In 1895 two French physicians attempted a radical departure from the standard cancer treatment regimen.
Updated July 9
Track COVID-19 Vaccines Advancing Through Clinical Trials
The Scientist | Apr 7, 2020 | 10+ min read
Find the latest updates in this one-stop resource, including efficacy data and side effects of approved shots, as well as progress on new candidates entering human studies.
The Proteasome: A Powerful Target for Manipulating Protein Levels
John Hines and Craig M. Crews | May 1, 2017 | 10+ min read
The proteasome’s ability to target and degrade specific proteins is proving useful to researchers studying protein function or developing treatments for diseases.
How Orphan Drugs Became a Highly Profitable Industry
Diana Kwon | May 1, 2018 | 10+ min read
Government incentives, advances in technology, and an army of patient advocates have spun a successful market—but abuses of the system and exorbitant prices could cause a backlash.

Run a Search

ADVERTISEMENT